Antiretroviral Current Events | Antiretroviral News | 4
|
| Page
4 of
8 |
156 Results |
|
|
|
Sort By:
Page Views | Date |
Efavirenz-Based Initial Therapies Associated with Better Outcomes in HIV-Infected Adults
A study led by researchers at the Johns Hopkins Bloomberg School of Public Health found that HIV-infected patients taking the antiretroviral drug efavirenz were more likely to adhere to treatment and less likely to experience virologic failure and death compared to patients taking nevirapine. view more (2008-10-15)
HIV drug maraviroc effective for drug-resistant patients
As many as one quarter of HIV patients have drug resistance, limiting their treatment options and raising their risk for AIDS and death. view more (2008-10-02)
Focusing HIV treatment helps control concurrent hepatitis B infection
Prolonged use of highly active antiretroviral therapy (HAART) to treat people infected with both HIV and hepatitis B (HBV) helps to better control the hepatitis B infection and could delay or prevent liver complications. view more (2009-07-15)
Six months after start of treatment could be optimum time for making prognosis in patients with HIV/AIDS (p 679)
Issue 30 August 2003 Embargoed 0001 h (London time) 29 August 2003. An international study in this week's issue of THE LANCET suggests that prognosis for patients with HIV/AIDS might be more reliably determined six months after initiation of highly active antiretroviral therapy (HAART), rather than before the start of treatment. HAART became... view more... (2003-08-27)
Socioeconomic Position Associated with Effectiveness of HIV Drugs, Even Among Subjects Adhering to Treatment Schedules
Socioeconomic position is a determinant of antiretroviral treatment effectiveness during initial therapy for HIV-1 infection. view more (2007-09-10)
HIV dementia alarmingly high in Africa
An international study led by Johns Hopkins suggests that the rate of HIV-associated dementia is so high in sub-Saharan Africa that HIV dementia along with Alzheimer's disease and dementia from strokes may be among the most common forms of dementia in the world. view more (2007-01-30)
Exciting Development in Anti-Retroviral Drug Discovery Made at Oxford
Researchers in Oxford University's Sir William Dunn School of Pathology have developed a novel HTS for identifying antiretroviral (HIV) agents/drugs that inhibit HIV infectivity. Current anti-viral drugs prolong the quality of life for many HIV-1+ individuals, but they do not stop the virus from infecting new cells. Since these drugs mostly... view more... (2003-06-05)
Cytomegalovirus infection still associated with poor HIV/AIDS prognosis (p 2101, 2116)
Results of a UK study in this week's issue of THE LANCET highlight how the treatment of cytomegalovirus infection remains a priority in order to improve the prognosis for people with HIV-1 infection, including people already receiving antiretroviral therapy. The advent of highly active antiretroviral therapy (HAART) at the end of the 20th century... view more... (2004-06-23)
Aids: A Single-Tablet Generic Tritherapy Tested Successfully In Cameroon
WHO's objective is to enable 3 million people living with HIV to have access to antiretroviral treatments by 2005. The development of simple and inexpensive generic fixed-dose combined therapies appears the most suitable solution for making possible this access to treatments in developing countries with meagre resources. The tritherapies that... view more... (2004-07-01)
Study shows common vitamin and other micronutrient supplements reduce risks of TB recurrence
New findings show a link between micronutrient supplementation and reduced risk of recurrence during tuberculosis chemotherapy, according to a study published in the June 1 issue of The Journal of Infectious Diseases, now available online. view more (2008-04-28)
Resistant HIV quickly hides in infants' cells
New evidence shows that drug-resistant virus passed from mother-to-child can quickly establish itself in infants' CD4+ T cells where it can hide for years, likely limiting their options for future treatment. view more (2007-05-01)
AIDS patients with serious complications benefit from early retroviral use, Stanford study shows
HIV-positive patients who don't seek medical attention until they have a serious AIDS-related condition can reduce their risk of death or other complications by half if they get antiretroviral treatment early on. view more (2009-05-18)
Study highlights HIV/AIDS challenge in American prison system
HIV/Aids is up to five times more prevalent in American prisons than in the general population. Adherence to treatment programs can be strictly monitored in prison. view more (2009-09-30)
The Lancet Oncology and The Lancet Infectious Diseases
THE LANCET ONCOLOGY THE TRUE COST OF A NUCLEAR DETERRENT This month’s editorial covers the recent leaked report from the US Department of Health and Disease Control, showing the patterns of nuclear fallout across the US resulting from Cold War testing. The editorial discusses the impact of these data on cancer incidence and the worldwide... view more... (2002-03-27)
First results of the Narval trial (ANRS 088)
Patients with HIV infection may develop resistance to one or more of antiretroviral drugs to which they are exposed during treatment. The selection of the most appropriate drugs for switching therapy in patients who have developed resistance, is a difficult challenge. Both, genetic tests that identify mutations in viral genes associated with... view more... (2000-04-21)
Study sets new gold standard for initial antiretroviral treatment of HIV infection
An international team of AIDS researchers at Johns Hopkins and other institutions has found that a once-daily combination of three antiretroviral drugs works better as an initial treatment for HIV infection than another three-drug combination long considered the gold standard. view more (2006-01-19)
PrEP strategy could dramatically slow the spread of HIV
Giving a daily antiretroviral pill to people to prevent HIV could profoundly slow the spread of the infection in sub-Saharan Africa, where it is a full-blown epidemic, University of Pittsburgh School of Medicine researchers report. view more (2007-09-19)
IL-2 immunotherapy fails to benefit HIV-infected individuals already taking antiretrovirals
Providing a synthetic form of the immune system protein interleukin-2 (IL-2) to HIV-infected individuals already taking combination antiretroviral therapy boosts their numbers of CD4+ T cells, the key white blood cells destroyed by HIV, but fails to reduce their risk of HIV-associated opportunistic diseases or death compared with combination... view more... (2009-02-11)
Having a stable partner delays AIDS in HIV patients
For people with HIV, having a stable partner is associated with slower rate of progression to AIDS or death, finds a study in this week's BMJ. Researchers in Switzerland followed 3,736 adults with HIV who had started highly active antiretroviral therapy (HAART) before 2002. Every six months, patients were asked whether they had had sexual... view more... (2004-01-03)
Taking medicine for HIV proves hard to swallow for many people
Highly active antiretroviral therapy has increased the longevity and quality of life for people living with human immunodeficiency virus. But it requires strict adherence in taking the medicine, something that is extremely difficult for many individuals to do. view more (2009-10-23)
|
|
| Page
4 of
8 |
156 Results |
|
|
|
Sort By:
Page Views | Date |
|
